AbCellera Biologics
ABCL
183 hedge funds and large institutions have $980M invested in AbCellera Biologics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 39 closing their positions.
504% more call options, than puts
Call options by funds: $13.3M | Put options by funds: $2.2M
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
0.5% more ownership
Funds ownership: 44.69% → 45.19% (+0.5%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
9% less funds holding
Funds holding: 201 → 183 (-18)
24% less capital invested
Capital invested by funds: $1.3B → $980M (-$316M)
41% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$8.44M |
| 2 |
Millennium Management
New York
|
+$7.08M |
| 3 |
Renaissance Technologies
New York
|
+$6.26M |
| 4 |
HF
HRT Financial
New York
|
+$5.05M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$8.89M |
| 2 |
TC
TwinBeech Capital
Purchase,
New York
|
-$5.31M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$3.58M |
| 4 |
Man Group
London,
United Kingdom
|
-$3.09M |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$2.06M |
ABCL Hedge Fund Activity: Q1 2023 in Review
183 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q1 2023, worth a combined $980M — down 24% from $1.3B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ABCL and 23 opened new positions — a net loss of 16 holders — while 54 trimmed existing stakes and 63 added.
The largest buyer was Norges Bank, adding an estimated $8.44M. The largest seller was D.E. Shaw & Co, cutting an estimated $8.89M.
- 183 institutional investors held AbCellera Biologics (ABCL) as of Q1 2023, down from 201 in Q4 2022.
- Funds reported $980M of AbCellera Biologics stock for Q1 2023, down 24% quarter-over-quarter.
- 23 funds opened new AbCellera Biologics positions in Q1 2023 and 39 closed out, a net change of -16 holders.
- The largest AbCellera Biologics buyer in Q1 2023 was Norges Bank, an estimated $8.44M added.
- The largest AbCellera Biologics seller in Q1 2023 was D.E. Shaw & Co, an estimated $8.89M sold.
Based on aggregated 13F filings for Q1 2023.